Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Mimedx (MDXG) Shares Outstanding (Diluted Average) (2016 - 2026)

Mimedx's Shares Outstanding (Diluted Average) history spans 15 years, with the latest figure at $148.4 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Diluted Average) fell 0.82% to $148.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $148.4 million, a 0.82% decrease, with the full-year FY2025 number at $149.7 million, changed 0.45% from a year prior.
  • Shares Outstanding (Diluted Average) hit $148.4 million in Q1 2026 for Mimedx, down from $149.7 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for MDXG hit a ceiling of $150.0 million in Q1 2024 and a floor of $111.6 million in Q1 2022.
  • Historically, Shares Outstanding (Diluted Average) has averaged $136.5 million across 5 years, with a median of $149.0 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): soared 32.02% in 2023 and later dropped 0.82% in 2026.
  • Tracing MDXG's Shares Outstanding (Diluted Average) over 5 years: stood at $112.9 million in 2022, then grew by 29.27% to $146.0 million in 2023, then rose by 2.11% to $149.0 million in 2024, then rose by 0.45% to $149.7 million in 2025, then decreased by 0.85% to $148.4 million in 2026.
  • Business Quant data shows Shares Outstanding (Diluted Average) for MDXG at $148.4 million in Q1 2026, $149.7 million in Q4 2025, and $149.6 million in Q3 2025.